Skip to content
Abzu logo
  • Pharma R&D
    • RNA Therapeutics
    • Exclusive partnerships
    • Research
    • Case study
  • Technology
    • About the QLattice®
    • Research publications
    • Gartner® research
    • Research collaborations
  • About Abzu
    • All about Abzu
    • Meet the Abzoids
    • Ethical AI use
    • Advisory board
    • Investors
    • Careers
  • Blog
  • News + media
    • All news and media
    • External media
    • Press releases
    • Awards
    • Podcasts
    • Videos
    • Events
  • Pharma R&D
    • RNA Therapeutics
    • Exclusive partnerships
    • Research
    • Case study
  • Technology
    • About the QLattice®
    • Research publications
    • Gartner® research
    • Research collaborations
  • About Abzu
    • All about Abzu
    • Meet the Abzoids
    • Ethical AI use
    • Advisory board
    • Investors
    • Careers
  • Blog
  • News + media
    • All news and media
    • External media
    • Press releases
    • Awards
    • Podcasts
    • Videos
    • Events
Contact us

Category: Case study

Abzu and NASA GeneLab study dermatological changes in spaceflight.

Abzu case study - NASA GeneLab

Abzu’s QLattice uniquely identified key “partner” genes involved in skin spaceflight response, a new discovery for how spaceflight damages skin.

Abzu identified which metabolites are present in early or late denning in bears.

Abzu case study - Black bears metabolite hibernation

Understanding how bears can hibernate without developing blood clots or muscle atrophy can help humans prepare for the future of space travel.

Abzu designed active and safe ASO and siRNA therapeutics.

Case study - Abzu and Contera Pharma

A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.

Abzu created a real-time LNP designer to predict apparent pKa value.

Case study - Abzu and undisclosed

Our models, interfaced through an application, allowed scientists to modify LNP properties and observe the direct impact.

Abzu reveals early predictive response biomarkers in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.

Abzu and Peptomyc case study

Stratifying patients at pretreatment by answering the question: Can we distinguish which patients will respond to OMO-103 treatment at baseline?

Abzu discovered key biomarkers for successful clinical trial of siRNA therapeutic.

Case study - Abzu and Checkmate Pharmaceuticals

Simple models accurately predicted and explained key biomarkers for successful clinical trial test of siRNA designed to downregulate.

Abzu increased safe ASOs by 20% over-and-above the in-house model.

Case study - Abzu and undisclosed

Abzu’s in-house activity models for RNA therapeutics are best-in-class for designing safe ASOs.

Pharma R&D.

  • RNA therapeutics
  • Exclusive partnerships
  • Research
  • Case studies

The QLattice®.

  • Research publications
  • Gartner® research
  • Research collaborations

About Abzu.

  • Meet the Abzoids
  • Ethical AI use
  • Advisory board
  • Investors
  • Careers

News + media.

  • External media
  • Press releases
  • Awards
  • Podcasts
  • Videos
  • Events
EU flag

Co-funded by the
European Union.

© 2025 Abzu Aps. All rights reserved. Abzu®, QLattice®, and Feyn® are registered trademarks.

Danish

 CVR DK39248530 

Spanish

 CIF B67165647

QLattice EULA

Privacy policy

Cookie-less policy

Security guide

LinkedIn
T
Instagram
Vimeo
YouTube
Medium
Discord
Spotify